Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1593371 | 0.86 | DGAT1 (0.38) | DGAT1NPC1PDE1BHSD17B10 | |
| SCHEMBL27215111 | 0.86 | DGAT1 (0.38) | DGAT1NPC1PDE1BHSD17B10 | |
| SCHEMBL27193468 | 0.85 | DGAT1 (0.37) | DGAT1PDE1B | |
| SCHEMBL19023210 | 0.85 | SPR (0.36) | DGAT1NPC1HSD17B10 | |
| SCHEMBL3299844 | 0.85 | NPC1 (0.33) | DGAT1NPC1 | |
| SCHEMBL23042416 | 0.85 | SPR (0.34) | DGAT1NPC1 | |
| SCHEMBL29705192 | 0.85 | SPR (0.34) | DGAT1NPC1 | |
| SCHEMBL27193478 | 0.84 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL24566116 | 0.84 | DGAT1 (0.37) | DGAT1PDE1B | |
| SCHEMBL24566902 | 0.83 | DGAT1 (0.36) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528791-B2 | Thyroid hormone receptor beta agonist compounds | TERNS PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20240150345-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | PHARMARON UK LTD. (GB) | 2024-05-09 | — | — | US | disclosed |
| US-20240116892-A1 | HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2024-04-11 | — | — | US | disclosed |
| EP-4167982-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230102554-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20220281849-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS PHARMACEUTICALS, INC. | 2022-09-08 | — | — | US | disclosed |
| WO-2022159745-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | HIBERCELL, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| EP-4017875-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns Pharmaceuticals, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3990443-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-114430743-A | Thyroid hormone receptor beta agonist compounds | 拓臻制药公司 | 2022-05-03 | — | — | CN | disclosed |
| WO-2021262596-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021041237-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2020264420-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020264420-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | GB002, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| EP-2344494-B1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| CN-103214480-B | Pyrazolopyridine alkynes benzene-like compounds and medicinal compositions thereof and application | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2015-12-16 | — | — | CN | disclosed |
| CN-103214480-A | Pyrazolopyridines alkynylbenzene compound and medicinal composition and application | GUANGZHOU INST BIOMED & HEALTH | 2013-07-24 | — | — | CN | disclosed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116892-A1 | HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS | JAK2, JAK1, JAK3 | DGAT1 2179/4885NPC1 4372/4885PDE1B 2544/4885 |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | DGAT1 2738/4885NPC1 2430/4885PDE1B 2625/4885 |
| US-12528791-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | DGAT1 2621/4885NPC1 1177/4885PDE1B 1236/4885 |
| US-20240150345-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | EIF2AK4, GCN1, CLN6 | DGAT1 565/4885NPC1 351/4885PDE1B 2867/4885 |
| US-20220281849-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | DGAT1 2786/4885NPC1 3364/4885PDE1B 723/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | DGAT1 2738/4885NPC1 2430/4885PDE1B 2625/4885 |
| US-20230102554-A1 | HETEROCYCLIC KINASE INHIBITORS AND PRODUCTS AND USES THEREOF | PDGFRB, PDGFRA, FGFR1 | DGAT1 4747/4885NPC1 4606/4885PDE1B 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.